Shanu Modi

16PUBLICATIONS
110CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Clinical midwiferyModels of care and place of birthSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 09, 2026
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer.

|Aug 20, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

|Nov 10, 2025
Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.

Wanyi Chen, Avantika Gupta, Nicholas Mai

|Oct 08, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Shanu Modi, William Jacot, Hiroji Iwata

|May 29, 2025
Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan.

|Mar 25, 2025
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study.

Shanu Modi, Suyuan Zhang, Danalyn Byng

Pageof 3

Frequent Collaborators

6 joint publications

Sarat Chandarlapaty

4 joint publications

Joshua Z Drago

3 joint publications

Pedram Razavi

3 joint publications

Nicholas Mai